Financial Performance - For the year ending December 31, 2025, the total comprehensive loss was RMB 305,972,000, a decrease of 21.1% from RMB 387,928,000 in 2024[3] - The company reported no revenue for the year 2025, compared to RMB 107,000 in 2024[5] - The group reported a loss before tax of RMB 305,972,000 for 2025, an improvement from a loss of RMB 387,928,000 in 2024, indicating a reduction in losses of about 21.1%[28] - The company's annual loss decreased by 21.1% from RMB 387.9 million in 2024 to RMB 306.0 million in 2025[83] - Basic and diluted loss per share improved to RMB 0.80 from RMB 1.15 in 2024[5] - The basic loss per share attributable to ordinary shareholders of the parent company for 2025 is RMB (0.80), compared to RMB (1.15) for 2024, indicating an improvement in performance[33] Research and Development - Research and development costs increased to RMB 244,064,000, up 3.7% from RMB 235,446,000 in 2024[3] - Research and development expenses for 2025 amounted to RMB 183,295,000, up from RMB 170,353,000 in 2024, reflecting an increase of approximately 7.6%[25] - R&D costs for the year ending December 31, 2025, amounted to RMB 244.1 million, a 3.7% increase from RMB 235.4 million in 2024, primarily due to milestone payments for TY-9591[77] - The R&D team consists of 117 members, with approximately 60% holding master's or doctoral degrees, covering all aspects of drug development[74] - The company has established a pipeline of 10 candidate drugs since its inception in 2017, including five clinical-stage products and four in early clinical development[52] Clinical Trials and Product Development - The core product TY-9591 has completed enrollment of 224 patients for its Phase II clinical trial for EGFR mutation lung cancer brain metastases, with a New Drug Application (NDA) submission expected in Q4 2025[44] - The company is conducting a Phase III clinical trial for TY-9591, with 541 patients enrolled as of July 2025, and expects to complete enrollment by Q4 2026[44] - The company has initiated a Phase II clinical trial for TY-302 in breast cancer and received ethics approval for a Phase II trial in prostate cancer as of July 2025[45] - TY-9591 demonstrated a median progression-free survival (PFS) of 19.3 months in EGFR L858R mutation lung cancer patients, compared to 14.4 months for osimertinib[61] - The NDA for TY-9591 has been accepted by the CDE and included in priority review for NSCLC brain metastases[54] Financial Position - Total assets decreased to RMB 779,737,000 from RMB 1,105,613,000 in 2024, reflecting a significant reduction in cash and bank balances[6] - Current liabilities increased to RMB 307,773,000 from RMB 289,081,000 in 2024, indicating a rise in trade and other payables[6] - The net asset value decreased to RMB 286,610,000 from RMB 472,562,000 in 2024, showing a decline in equity[7] - The total non-current assets decreased from RMB 74,471,000 in 2024 to RMB 44,157,000 in 2025, primarily due to a reduction in long-term asset prepayments[37] - As of December 31, 2025, the company's borrowings amounted to RMB 134,115,000, down from RMB 144,175,000 as of December 31, 2024, with a debt-to-asset ratio of approximately 63.2%[88] Regulatory and Compliance - Hong Kong Financial Reporting Standard No. 18 introduces new presentation requirements for the income statement, categorizing all income and expenses into five categories: operating, investing, financing, income tax, and discontinued operations[14] - The new standards and amendments are effective for annual periods beginning on or after January 1, 2027, with retrospective application required[14] - The company is currently analyzing the impact of the new regulations on its financial statement presentation and disclosures[14] - The audit committee consists of two independent non-executive directors and one non-executive director, with Mr. Jiang Xiaolin as the chairman[113] Shareholder and Governance - The annual general meeting is scheduled for June 23, 2026, with the H-share register closing from June 17 to June 23, 2026[117][118] - Proposed amendments to the company's articles of association include compliance with the latest regulatory requirements and the addition of audit, nomination, and remuneration committee powers[120] - The company will provide various methods, including online and electronic communication, for shareholders to participate in meetings, ensuring their attendance is recognized[122] - The company is committed to adhering to corporate governance codes as per the listing rules[128] Cash Flow and Financing - The net cash used in operating activities for the year ended December 31, 2025, was RMB 215,768,000, primarily due to a pre-tax loss of RMB 305,972,000[84] - The net cash generated from financing activities was RMB 126,384,000, primarily from new bank loans of RMB 110,000,000 and net proceeds from placements of RMB 141,366,000[85] - The company's capital expenditure during the reporting period totaled approximately RMB 39,413,000, mainly for the purchase of properties, plants, and equipment[87] Market and Commercialization Strategy - The company is actively expanding its commercialization team to enhance brand promotion and market potential through various academic and industry collaborations[75] - The company plans to adopt a strategy combining external collaboration and self-construction for commercialization, initially partnering with experienced external partners to enhance market expansion and brand promotion[100] - The company aims to transition from collaborative efforts to a primarily self-operated commercialization model, enhancing its core operational capabilities[100]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 自願公告 本公司及本新聞所涉及的本公司未對發佈的信息作出任何明示或暗示的陳述或保 證。儘管本公司盡力確保信息的準確性，但仍可能存在不準確或遺漏。信息可能 未涵蓋所有相關因素，且可能因解釋方法不同而產生不同結論。預測和觀點具有 推測性，基於未來市場、客戶行為和技術發展的假設，可能存在較大誤差。信息 和觀點僅截至發佈之日，可能隨時變化，且不會因後續發展而更新。 本公司及其關聯方，以及其董事、高管、員工、顧問或代表，均不對因使用或依 賴本新聞中的信息，或基於信息所做出的任何決策而產生的任何損失承擔責任 （包括因疏忽、虛假陳述、遺漏或其他原因）。 技術詞彙表 | 「CDK」 | 細胞週期蛋白依賴性激酶 | | --- | --- | | 「EGFR」 | 表皮生長因子受體 | | ...

承董事會命 浙江同源康醫藥股份有限公司 董事長、執行董事兼總裁 吳豫生博士 香港，2026年3月18日 （股份代號：2410） 董事會會議日期 浙江同源康醫藥股份有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，董 事會會議將於2026年3月30日（星期一）舉行，藉以（其中包括）考慮及批准本公司 及其附屬公司截至2025年12月31日止年度之全年業績及其刊發，以及考慮派發末 期股息（如有）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 於本公告日期，董事會成員包括執行董事吳豫生博士，非執行董事李鈞博士、顧 虹博士、蔣鳴昱博士、何超先生及朱向陽博士，獨立非執行董事冷瑜婷博士、許 文青博士、沈秀華博士及江曉林先生。 ...

FF305 第 1 頁 共 6 頁 v 1.3.0 | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | 於香港聯交所上市 | 否 | | | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 非上市股份 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2026年2月28日 | 4,608,000 | | 0 | | 4,608,000 | | 1). 其他 (請註明) | | -4,608,000 | 100 % | | | | | 於2026年3月4日轉換4,608,000非上市股份為4,608,000本公司H股 （有關詳情載於本公司日期為2026年 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 內幕消息 完成H股全流通 完成H股全流通 本公司董事會欣然宣佈，4,608,000股非上市股份已於2026年3月4日完成轉換為H 股，該等經轉換H股將於2026年3月5日上午九時正開始於聯交所上市。 1 股權架構 緊接轉換及上市完成前及於轉換及上市完成後，本公司的股本結構載列如下： | 股份類別 | 於本公告日期 | | 於轉換及上市完成後 | | | --- | --- | --- | --- | --- | | | | 概約百分比 | | 概約百分比 | | | 股份數目 | % | 股份數目 | % | | H股 | 375,457,818 | 98.79% | 380,065,818 | 100.00% | | 非上市股份 | 4,608,000 | 1.21% | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 浙江同源康醫藥股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02410 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 375,457,818 | RMB | | 1 RMB | | 375,457,818 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 375,457,818 | RMB | | 1 RMB | | 375,457,818 | | 2. 股 ...

Core Viewpoint - The company is undergoing a capital increase for its subsidiary, Tongyuan Kang Biological, which will result in a significant reduction of its ownership stake and the subsidiary will no longer be a part of the group [1][2] Group 1: Capital Increase Details - The company and existing shareholders have entered into a capital increase agreement to raise approximately RMB 83.5 million, increasing the registered capital of Tongyuan Kang Biological from approximately RMB 14.0 million to about RMB 20.49 million [1] - Following the capital increase, the company's equity interest in Tongyuan Kang Biological will decrease from approximately 57.14% to 39.03% [1] - The capital increase is considered a disposal transaction due to the reduction in the company's shareholding [1] Group 2: Business Implications - Tongyuan Kang Biological is a biopharmaceutical company focused on dual antibodies, tri-antibodies, and ADC, operating independently from the group's core business [2] - The capital increase is expected to provide operational funding for Tongyuan Kang Biological, which is in its early stages and will require significant capital before commercialization [2] - The terms of the capital increase agreement were negotiated fairly and are based on normal commercial terms, considering the operational funding needs of Tongyuan Kang Biological and the contributions expected from investors [2]

Core Viewpoint - The company announced a capital increase agreement involving existing shareholders and several investors, which will lead to a significant reduction in its ownership stake in a subsidiary, 同源康生物, from approximately 57.14% to 39.03% [1] Group 1: Capital Increase Details - The total consideration for the capital increase is approximately RMB 83.5 million, which will increase the registered capital of 同源康生物 by about RMB 6.49 million [1] - Following the capital increase, the total registered capital of 同源康生物 will rise from RMB 14 million to approximately RMB 20.49 million [1] Group 2: Strategic Implications - 同源康生物 is a biopharmaceutical company focused on dual antibodies, triple antibodies, and ADC, and will no longer be a subsidiary of the group after the capital increase [1] - The capital increase is expected to provide operational funding for 同源康生物, which is in an early-stage startup phase and will require significant funding before achieving commercialization [1] - This transaction allows the group to concentrate its resources on other operational aspects while retaining a significant interest and level of participation in 同源康生物 [1]

Core Viewpoint - The company Tongyuan Kang Pharmaceutical-B (02410) announced a capital increase agreement that will dilute its ownership in Tongyuan Kang Biotechnology from approximately 57.14% to 39.03% after the completion of the capital increase, which is expected to enhance operational funding for the biotechnology firm [1] Group 1: Capital Increase Details - The total consideration for the capital increase is approximately RMB 83.5 million [1] - The registered capital of Tongyuan Kang Biotechnology will increase from RMB 14 million to approximately RMB 20.49 million [1] - The agreement involves existing shareholders including the company itself and several investment firms [1] Group 2: Company Operations and Strategy - Tongyuan Kang Biotechnology is a biopharmaceutical company focusing on dual antibodies, triple antibodies, and ADCs, operating independently from the core business of the group [1] - The capital increase is expected to provide necessary operational funds for Tongyuan Kang Biotechnology, which is in an early-stage startup phase and anticipates significant funding needs before achieving commercialization [1] - This transaction allows the group to concentrate its resources on other operational aspects while retaining significant equity and involvement in Tongyuan Kang Biotechnology [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 於2026年2月27日（交易時段後），現有股東（包括本公司）、同源康生物及認購 人訂立增資合同，據此，訂約方同意以總代價約人民幣83.5百萬元增加同源康 生物的註冊資本約人民幣6.49百萬元。增資完成後，同源康生物之總註冊資本 將由人民幣14.0百萬元增加至約人民幣20.49百萬元，而本公司於同源康生物之 權益將由約57.14%減少至39.03%，且同源康生物將不再為本集團之附屬公司。 由於增資將導致削減本公司於同源康生物的持股量，故構成視作出售事項。本 公司董事長兼總裁吳豫生博士於長興同源（為認購人之一）的普通合夥人中間接 擁有33.30%權益。因此，訂立增資合同根據上市規則第十四A章構成本公司的 一項關連交易。 （股份代號：2410） 關連交易 視作出售一間附屬公司 上市規則的涵義 由於有關增資及先前增資的最高適用百分比率超過0.1%但低於5%，增資及先前 增資（均於增資合同日期前12個月內發生，故根 ...